SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that it has entered into definitive agreements with its commercial partner, Nippon Shinyaku, Co., Ltd.

圣地亚哥，2023年9月29日（GLOBE NEWSWIRE）-Capricor Therapeutics（纳斯达克股票代码：CAPR），一家专注于开发用于治疗和预防肌肉和其他选择性疾病的转化细胞和基于外泌体的疗法的生物技术公司，今天宣布已与其商业合作伙伴日本新雅库有限公司签订明确协议。

and funds associated with Highbridge Capital Management, LLC. for the issuance and sale of 4,935,621 shares of its common stock in a registered direct offering. Each share of common stock offered was sold with a warrant to purchase one share of common stock at an exercise price of $5.70 per share. Each warrant will be exercisable beginning six months after issuance and will expire seven years from the date of issuance.

以及与Highbridge Capital Management，LLC。相关的资金，用于在注册直接发行中发行和销售其普通股的4935621股股票。所提供普通股的每股股份均以行使价5.70美元购买一股普通股的认股权证出售。每份认股权证将于发行后六个月开始行使，并将于发行之日起七年到期。

The combined offering price per share of common stock and accompanying warrant is $4.66. The closing of the offering is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds to the Company from the offering are expected to be approximately $23 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.

普通股及随附认股权证合价为4.66美元。在满足习惯性结算条件的前提下，预计将于2023年10月3日或之后结束发行。在扣除安置代理人的费用和本公司应付的其他提供费用之前，本公司从该提供中获得的所得总额预计约为2300万美元。

The Company intends to use the net proceeds from this offering on research and development related to its product candidates, manufacturing of its products, working capital and general corporate purposes. Cantor Fitzgerald & Co. is acting as the sole lead-placement agent for the offering. H.C. Wainwright & Co.

本公司打算将本次发行的净收益用于与其候选产品，产品制造，营运资本和一般公司用途相关的研发。Cantor Fitzgerald＆Co。是该产品的唯一主要代理商。H、 C.Wainwright＆Co。

is acting as the co-placement agent for the offering. The securities are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-254363) that was originally filed with the Securities and Exchange Commission (.

正在充当该产品的合作代理商。本公司根据最初向证券交易委员会提交的表格S-3（文件编号333-254363）上的有效货架注册声明提供证券（。